Cell-Free (RNA) and Cell-Associated (DNA) HIV-1 and Postnatal Transmission through Breastfeeding

listen audio

Study Justification:
This study aimed to investigate the relationship between cell-free (RNA) and cell-associated (DNA) shedding of HIV-1 virus in breastmilk and the risk of postnatal HIV-1 transmission in the first 6 months postpartum. The justification for this study is that transmission through breastfeeding remains important for mother-to-child transmission (MTCT) in resource-limited settings. Understanding the factors that contribute to postnatal HIV-1 transmission can help inform strategies to reduce transmission rates and improve the health outcomes of HIV-exposed infants.
Highlights:
– The study found that there were higher levels of cell-free HIV-1 virus in breastmilk compared to cell-associated virus at 6 weeks and 6 months postpartum.
– The association between virus levels and risk of postnatal HIV-1 transmission differed between cell-free and cell-associated virus. At 6 weeks, cell-associated virus levels were more strongly associated with transmission, while at 6 months, cell-free virus levels were more strongly associated.
– These findings suggest that cell-associated virus levels may be more important for early postpartum HIV-1 transmission, highlighting a potential challenge for resource-limited settings to eliminate vertical transmission.
– The study emphasizes the need for further research to understand the mechanisms of HIV-1 transmission and develop more effective drugs for lactating mothers.
Recommendations:
Based on the study findings, the following recommendations can be made:
1. Strategies to reduce cell-associated virus levels in breastmilk should be explored to minimize the risk of early postpartum HIV-1 transmission.
2. Further research is needed to understand the mechanisms of HIV-1 transmission through breastfeeding and develop interventions to prevent transmission.
3. Efforts should be made to improve access to antiretroviral therapy for lactating mothers in resource-limited settings to reduce both cell-free and cell-associated virus levels in breastmilk.
4. Public health programs should prioritize the elimination of vertical transmission of HIV-1 through breastfeeding by implementing comprehensive prevention and treatment strategies.
Key Role Players:
To address the recommendations, the following key role players are needed:
1. Researchers and scientists to conduct further studies on HIV-1 transmission through breastfeeding and develop effective interventions.
2. Healthcare providers to implement prevention and treatment strategies, including the provision of antiretroviral therapy to lactating mothers.
3. Policy makers and government officials to allocate resources and develop policies that support the elimination of vertical transmission of HIV-1.
Cost Items:
While the actual cost of implementing the recommendations is not provided, the following cost items should be considered in planning:
1. Research funding for further studies on HIV-1 transmission through breastfeeding and the development of interventions.
2. Costs associated with providing antiretroviral therapy to lactating mothers, including medication, healthcare personnel, and monitoring.
3. Costs of implementing public health programs and interventions to prevent vertical transmission of HIV-1 through breastfeeding, such as education and awareness campaigns, training of healthcare providers, and monitoring and evaluation systems.

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is moderately strong. The study design is a case-control study nested in a cohort, which provides a good level of evidence. The study analyzes the relationship between cell-free and cell-associated shedding of HIV-1 virus in breastmilk and the risk of postnatal HIV-1 transmission. The study includes a relatively small sample size of 36 transmitting mothers and 36 control mothers. The statistical analysis is appropriate, adjusting for confounding factors. However, the abstract does not provide information on the representativeness of the study population or the generalizability of the findings. To improve the evidence, future studies could include a larger sample size and provide more information on the study population and setting.

Introduction: Transmission through breastfeeding remains important for mother-to-child transmission (MTCT) in resource-limited settings. We quantify the relationship between cell-free (RNA) and cell-associated (DNA) shedding of HIV-1 virus in breastmilk and the risk of postnatal HIV-1 transmission in the first 6 months postpartum. Materials and Methods: Thirty-six HIV-positive mothers who transmitted HIV-1 by breastfeeding were matched to 36 non-transmitting HIV-1 infected mothers in a case-control study nested in a cohort of HIV-infected women. RNA and DNA were quantified in the same breastmilk sample taken at 6 weeks and 6 months. Cox regression analysis assessed the association between cell-free and cell-associated virus levels and risk of postnatal HIV-1 transmission. Results: There were higher median levels of cell-free than cell-associated HIV-1 virus (per ml) in breastmilk at 6 weeks and 6 months. Multivariably, adjusting for antenatal CD4 count and maternal plasma viral load, at 6 weeks, each 10-fold increase in cell-free or cell-associated levels (per ml) was significantly associated with HIV-1 transmission but stronger for cell-associated than cell-free levels [2.47 (95% CI 1.33-4.59) vs. aHR 1.52 (95% CI, 1.17-1.96), respectively]. At 6 months, cell-free and cell-associated levels (per ml) in breastmilk remained significantly associated with HIV-1 transmission but was stronger for cell-free than cell-associated levels [aHR 2.53 (95% CI 1.64-3.92) vs. 1.73 (95% CI 0.94-3.19), respectively]. Conclusions: The findings suggest that cell-associated virus level (per ml) is more important for early postpartum HIV-1 transmission (at 6 weeks) than cell-free virus. As cell-associated virus levels have been consistently detected in breastmilk despite antiretroviral therapy, this highlights a potential challenge for resource-limited settings to achieve the UNAIDS goal for 2015 of eliminating vertical transmission. More studies would further knowledge on mechanisms of HIV-1 transmission and help develop more effective drugs during lactation. © 2012 Ndirangu et al.

HIV-infected and HIV-uninfected women were enrolled in an intervention cohort study, between August 2001 and September 2004 [22], [23], to investigate whether breastfeeding in a high HIV prevalence, poor rural setting in South Africa could be made safe in terms of both HIV-1 transmission and infant morbidity and mortality. Weekly home visits documented infant feeding and morbidity while clinic follow-up of the infants and mothers were scheduled monthly between 6 weeks and 9 months. Ten milliliters of breastmilk were collected from each breast for HIV-infected and uninfected breastfeeding mothers at each scheduled clinic visit. Samples were transported and maintained at 4 degrees Celsius overnight and stored long-term as whole breastmilk at minus 80 degrees Celsius until testing. A dried blood spot for each infant was collected at each visit and stored at minus 20 degrees Celsius. HIV-1 RNA quantification was performed using the Nuclisens HIV-1 QT assay (Organon Teknika, Boxtel, Netherlands) and Nuclisens EasyQ HIV-1 assay (Biomerieux, Boxtel, Netherlands) with a sensitivity of 80 copies HIV-1 RNA per ml of blood (equivalent to 1600 copies HIV-1 RNA per 50 µl dried blood spot) [24]. Rates of MTCT of HIV-1 during breastfeeding have been described previously [23]. Children were considered infected through breastfeeding if they had a negative HIV polymerase chain reaction (PCR) assay at 6 weeks of age and a positive PCR at any time thereafter. Single-dose nevirapine (sdNVP) for use during labour/delivery was provided for all HIV-infected women and to their newborns; ART for treatment or as MTCT prophylaxis from early in pregnancy or during the postnatal period was not available in the public health setting at the time of this study. Maternal viral load and CD4 count were collected antenatally. The project was approved by the Biomedical Ethics Review Committee (BREC) at the University of KwaZulu-Natal South Africa. A case-control study was nested in this intervention cohort [22]. The primary study identified 42 babies who had acquired HIV infection postnatally (as diagnosed by PCR conversion) [23]. Our study includes 36 postnatally infected children who had both cell-free and cell-associated data on samples at 6 weeks and 6 months, and who were matched to controls. Cases and controls were matched (in a 1∶1 ratio) on infant age at breastmilk sampling with a maximum allowance of 2 weeks of the sample date of the case to reduce potential bias of varying concentrations of breastmilk RNA and DNA over time [25]. Cases were mothers who transmitted HIV-1 to their infants through breastmilk between 6 and 28 weeks postpartum while controls were non-transmitting HIV-1 infected mothers. Transmission was estimated to have occurred at the midpoint between an infant’s last HIV negative PCR test and first positive result. Infants were included if they had at least one cell-free and one cell-associated breastmilk sample available close to the estimated time of transmission (ETT). Breastmilk samples from both breasts, for postnatal transmitters and controls had DNA quantified twice (at 6 weeks and 6 months) and RNA at multiple time points before 6 months. Thirty-six transmitting mothers had 85 samples tested for HIV-1 RNA and DNA in both left and right breast; 36 control mothers had 81 samples. This study differs from the previous study which investigated the association between postnatal HIV acquisition at 6–28 weeks and cumulative cell-free HIV exposure (i.e. the overall amount of cell-free viral particles ingested by the infant during breastfeeding, upto infection or equivalent age of control) [19]. The volume of milk ingested per day was estimated by pattern of feeding and the probability of transmission estimated per liter of breastmilk ingested. However, that study did not access the influence of cell-associated virus integrated in latent T cells on postnatal transmission. In contrast, the current study presents the association between cell-free and cell-associated shedding of HIV-1 virus in breastmilk and postnatal HIV-1 transmission. Cell-free HIV-1 quantification on breastmilk samples was performed as described previously [19]. Cell-associated HIV-1 quantification on whole breastmilk samples was performed using the Generic HIV DNA Cell assay (Biocentric, Bandol, France). Breastmilk samples were thawed at room temperature and vortex mixed. A maximum of 1.5 ml (range 0.5–1.5 ml) of breastmilk was aliquoted into a 2 ml microtube, centrifuged at 2000 g for 15 min and the lactoserum-lipid layer was removed to a 1.5 ml microtube. The lactoserum-lipid fraction was stored at −80°C. The remaining breastmilk pellet was used in the HIV DNA real time PCR (qPCR) assay. RNA was isolated from 500 µL of lactoserum with use of the magnetic particle-based ASPS method (Abbott), and HIV load was quantified using the Generic HIV Charge Virale assay (Biocentric, Bandol, France) on the MJ MiniOpticon quantitative PCR detection platform (Biorad), with a sensitivity of 375 copies per mL of lactoserum [26]. This method enabled accurate assessment of cell-free viral load entrapped by lipids [27]. The Qiagen DNA Mini Kit was used to isolate total DNA from the dry breastmilk pellet according to the manufacturer’s instructions. Total DNA concentration was measured with the Nanodrop instrument using 1 µl of sample. Samples with a DNA concentration of 50 ng/µl an appropriate dilution of up to 1∶10 was performed. The total reaction volume was 50 µl with a 20 µl sample input volume, according to manufacturer’s instructions. The human GAPDH housekeeping gene (Primer_F : 5′-AAGGTCGGAGTCAACGGATT-3′; Primer_R R: 5′-CTCCTGGAAGATGGTGATGG-3′) was quantified by real-time PCR using SybrGreen to verify the integrity of the extracted DNA, to determine the presence or absence of inhibitors/contaminants, and to act as a reference gene for quantitative analysis [28]–[30]. Quantifying the host gene GAPDH provided an estimate of the number of cells per PCR, allowing expression of the number of copies of HIV per 106 cells in our sample despite not having a cell count. The analyses included transmitters and controls with both cell-free and cell-associated results available from the same breastmilk sample at 6 weeks and 6 months. When the 6 months results were more than 4 weeks after transmission, the RNA result closest to the transmission was used (RNA was quantified at multiple time points) while the average between the two DNA results was calculated, otherwise the result at 6 months was used. Breastmilk HIV-1 RNA viral load levels below the lower detectable limit (375 copies/ml) were assigned a value at the midpoint between this and zero (187.5 copies/ml) [31], [32]. Breastmilk HIV-1 DNA samples below the lower detectable limit were normalized for the amount of cells used to isolate the DNA (based on the GAPDH measurement which is different for each cell) [33]. No breastmilk samples were excluded because of low cell counts as all samples had DNA values above zero. Cell-free and cell-associated virus levels were analyzed on a decimal logarithmic scale to base-10 [11], [18]. Counts of DNA quantified per million cells were converted to concentrations of DNA per milliliter by multiplying by 0.08×106 at 6 weeks and 0.05×106 at 6 months breastmilk cells per milliliter, as suggested in previous studies [11], [34]. Chi-square test assessed differences in categorical variables while Wilcoxon rank-sum test was used for non-parametric analysis of continuous variables. Spearman rank correlation estimated correlation between continuous variables. Cox regression models, pooling multiple measurements from the left and right breastmilk samples, assessed the association between breastmilk cell-free and cell-associated virus levels and risk of postnatal HIV-1 transmission. Observation time was taken from 6 weeks of age (last negative HIV PCR assay) to the estimated time of HIV-1 infection or end of observation (6 months of age), whichever came first. Multivariable models included maternal antenatal CD4 cell count and plasma RNA [18], and were stratified by time (6 weeks and 6 months) because there are more infected cells in early than mature breastmilk [11]. The model adjusting for both antenatal CD4 count and viral load represented the best fit of the data using BIC and was thus retained as the final model. Data were analysed using Stata Version 11.2 (2009 StataCorp, College Station, Texas, USA).

N/A

Based on the provided information, here are some potential innovations that could improve access to maternal health:

1. Point-of-care testing: Develop and implement rapid and accurate diagnostic tests for HIV-1 RNA and DNA in breastmilk that can be performed at the point of care. This would allow for real-time monitoring of viral levels and timely interventions to prevent transmission.

2. Mobile health (mHealth) interventions: Utilize mobile technology to provide educational resources, reminders, and support to HIV-positive mothers regarding breastfeeding practices, antiretroviral therapy adherence, and infant care. This could help improve maternal and infant health outcomes.

3. Novel antiretroviral therapies: Research and develop new antiretroviral drugs specifically designed to target cell-associated HIV-1 virus in breastmilk. These drugs could be more effective in reducing transmission and be better suited for resource-limited settings.

4. Community-based interventions: Implement community-based programs that provide comprehensive support to HIV-positive mothers, including access to healthcare services, counseling, and peer support. This would help address barriers to care and improve maternal health outcomes.

5. Integration of services: Integrate maternal health services with existing HIV/AIDS programs to ensure that HIV-positive mothers receive comprehensive care and support throughout the breastfeeding period. This would help streamline care and improve access to necessary interventions.

6. Capacity building: Invest in training and capacity building for healthcare providers in resource-limited settings to ensure they have the knowledge and skills to effectively manage and support HIV-positive mothers during the breastfeeding period. This would help improve the quality of care and reduce transmission rates.

7. Policy and advocacy: Advocate for policy changes and increased funding to support maternal health programs, including those focused on preventing mother-to-child transmission of HIV. This would help create an enabling environment for innovation and improve access to care for all mothers.

It is important to note that these recommendations are based on the specific context and findings described in the provided information. Further research and evaluation would be needed to determine the feasibility and effectiveness of these innovations in improving access to maternal health.
AI Innovations Description
The recommendation to improve access to maternal health based on the provided information is to conduct more studies to further understand the mechanisms of HIV-1 transmission through breastfeeding and develop more effective drugs during lactation. This is important because the study found that cell-associated virus levels in breastmilk are more important for early postpartum HIV-1 transmission than cell-free virus levels. Despite antiretroviral therapy, cell-associated virus levels have been consistently detected in breastmilk, posing a challenge for resource-limited settings to achieve the goal of eliminating vertical transmission. By conducting more studies, researchers can gain a deeper understanding of HIV-1 transmission and develop better drugs to prevent transmission during breastfeeding.
AI Innovations Methodology
Based on the provided information, here are some potential recommendations to improve access to maternal health:

1. Implement mobile health (mHealth) interventions: Utilize mobile technology to provide maternal health information, reminders for prenatal and postnatal care appointments, and access to telemedicine consultations.

2. Strengthen community-based healthcare services: Establish and support community health workers who can provide essential maternal health services, including prenatal care, education, and postnatal support.

3. Improve transportation infrastructure: Enhance transportation networks in rural and remote areas to ensure that pregnant women can easily access healthcare facilities for prenatal and postnatal care.

4. Expand access to antenatal and postnatal care: Increase the number of healthcare facilities offering antenatal and postnatal care services, particularly in underserved areas.

5. Enhance health education programs: Develop and implement comprehensive health education programs that focus on maternal health, including family planning, nutrition, and breastfeeding.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define the target population: Identify the specific population that will be impacted by the recommendations, such as pregnant women in a particular region or community.

2. Collect baseline data: Gather data on the current state of maternal health access in the target population, including factors such as healthcare facility availability, transportation options, and utilization of antenatal and postnatal care services.

3. Develop a simulation model: Create a mathematical or computer-based model that simulates the impact of the recommendations on improving access to maternal health. This model should consider factors such as the number of healthcare facilities, transportation infrastructure, and utilization rates of antenatal and postnatal care services.

4. Input data and parameters: Input the baseline data and parameters into the simulation model, including information on the target population, the recommended interventions, and any other relevant variables.

5. Run simulations: Run multiple simulations using different scenarios and assumptions to assess the potential impact of the recommendations on improving access to maternal health. This could include variations in the number of healthcare facilities, transportation options, and utilization rates of antenatal and postnatal care services.

6. Analyze results: Analyze the results of the simulations to determine the potential impact of the recommendations on improving access to maternal health. This could include assessing changes in healthcare facility utilization rates, travel distances to healthcare facilities, and overall improvement in maternal health outcomes.

7. Refine and iterate: Based on the results of the simulations, refine the recommendations and simulation model as needed. Repeat the simulation process to further assess the potential impact of the refined recommendations.

By following this methodology, policymakers and healthcare providers can gain insights into the potential impact of different recommendations on improving access to maternal health and make informed decisions on implementing the most effective interventions.

Share this:
Facebook
Twitter
LinkedIn
WhatsApp
Email